Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | APEX1 | P27695 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.34 |
| ▸ | ARG1 | P05089 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29596201 | 0.85 | CA2 (0.52) | CA2ALDH1A1ARG1 | |
| SCHEMBL7204059 | 0.80 | CA2 (0.33) | CA2ARG1 | |
| SCHEMBL26901492 | 0.78 | APP (0.44) | CA2ALDH1A1MEN1POLBAPEX1 | |
| SCHEMBL8315940 | 0.77 | ARG1 (0.32) | CA2ARG1 | |
| SCHEMBL2818804 | 0.76 | ALDH1A1 (0.69) | CA2ALDH1A1MEN1POLBAPEX1 | |
| SCHEMBL13668109 | 0.73 | CA2 (0.37) | CA2ARG1 | |
| SCHEMBL8314520 | 0.71 | FFAR1 (0.34) | CA2ARG1 | |
| SCHEMBL6148010 | 0.70 | CA1 (0.37) | CA2ARG1 | |
| SCHEMBL8313149 | 0.70 | CA2 (0.31) | CA2ARG1 | |
| SCHEMBL10457263 | 0.69 | CA2 (0.43) | CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12168653-B2 | Sulfonamide derivates as NLRP3 inhibitors | INFLAZOME LIMITED (IE) | 2024-12-17 | — | — | US | disclosed |
| US-12030879-B2 | Sulfonyl acetamides as NLRP3 inhibitors | INFLAZOME LIMITED (IE) | 2024-07-09 | — | — | US | disclosed |
| US-20210002274-A1 | NOVEL COMPOUNDS | INFLAZOME LIMITED (IE) | 2021-01-07 | — | — | US | disclosed |
| US-20210002274-A1 | NOVEL COMPOUNDS | INFLAZOME LIMITED (IE) | 2021-01-07 | — | — | US | disclosed |
| US-20200407340-A1 | SULFONAMIDE DERIVATES AS NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2020-12-31 | — | — | US | disclosed |
| US-20200407340-A1 | SULFONAMIDE DERIVATES AS NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2020-12-31 | — | — | US | disclosed |
| EP-2655362-A1 | HEPATITIS C INHIBITORS AND USES THEREOF | Abbvie Inc. (US) | 2013-10-30 | — | — | EP | disclosed |
| WO-2012087833-A1 | HEPATITIS C INHIBITORS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030879-B2 | Sulfonyl acetamides as NLRP3 inhibitors | NLRP3, NOD1, NLRP1 | CA2 624/4885ALDH1A1 1078/4885MEN1 3575/4885 |
| US-20200407340-A1 | SULFONAMIDE DERIVATES AS NLRP3 INHIBITORS | NLRP3, NOD1, NLRP1 | CA2 1163/4885ALDH1A1 1246/4885MEN1 4263/4885 |
| US-20210002274-A1 | NOVEL COMPOUNDS | NLRP3, NOD1, NLRP1 | CA2 1129/4885ALDH1A1 1160/4885MEN1 2685/4885 |
| US-12168653-B2 | Sulfonamide derivates as NLRP3 inhibitors | NLRP3, NOD1, NLRP1 | CA2 1163/4885ALDH1A1 1246/4885MEN1 4263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.